WHO ICTRP trial
International treatment-extension study in adult participants with multiple…
JPRN-jRCT2031230009 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031230009 |
|---|---|
| Public title | International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab |
| Scientific title | International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study |
| Primary sponsor | Tanaka Tomoyuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | Finland;Japan;Czech Republic;Japan;Sweden;Japan |
| Conditions | Plasma cell myeloma |
| Interventions | Drug: Isatuximab (SAR650984) Pharmaceutical form: Vial Route of administration: IV infusion Drug: Dexamethasone Pharmaceutical form: Tablets Route of administration: Oral Drug: Pomalidomide Pharmaceutical form: Hard capsules Route of… |
| Registration date | Jul 4, 2023 |
| Target size | 70 |
| Secondary IDs | NCT05669989;2022-002253-26 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: